BIOLIFE4D has started a $50 million Reg A+ offering that will fund its work to create a replacement for the human heart through a 3-D printing process. Down the road, the company sees the potential for replicating other human organs.
“Once our process for 3D bioprinting a heart is optimized, we can leverage the technology and look to apply it to other vital organs,” company president, founding partner and CEO Steven Morris told The Deal.
Morris told The Deal that printing a new heart involves changing existing DNA.
“The 3D bioprinting process is just a type of reprogramming,” Morris said.
Read more HERE